Two-quadrant anaesthesia technique reduces pain during vitrectomy

Article

Using two-quadrant sub-Tenon's anaesthesia is more effective at reducing intraoperative and postoperative pain than a single-quadrant technique.

Using two-quadrant sub-Tenon's anaesthesia is more effective at reducing intraoperative and postoperative pain than a single-quadrant technique, states a study in the British Journal of Ophthalmology.

Dr Vip S. Gill et al., Department of Anaesthesia, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK, studied 54 patients undergoing vitrectomy. All patients were equally randomized into two groups.

Group A, the control, were administered a standard 5 ml single inferonasal sub-Tenon injection of 2% lidocaine and 0.5% bupivacaine in a 50:50 mixture. Group B, the study group, received a 5 ml inferonasal and 5 ml superotemporal injection.

Primary outcome measures included amount of intraoperative top-ups needed and the secondary outcome measures included intraoperative and postoperative pain scores, IOP, block onset time, ocular akinesia, eyelid akinesia and chemosis.

In the group V there were no patients requiring an anaesthetic top-up, but in the control group a top-up was needed in 24 patients. In group B block onset was shorter, eyelid akinesia was improved and pain scores were reduced intraoperatively and 0–2 hours (h), 4–6 h, 10–14 h and 20–24 h postoperatively.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.